PetMed Express, Inc.

PETS Healthcare Pharmaceutical Retailers

PetMed Express, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $179.0 million, down 21.1% from fiscal 2025. In the quarter to June 2026, revenue fell 19.9%, EPS grew 83.0% and free cash flow grew 38.6%, each against the same quarter a year earlier. Dividend growth for ten consecutive years; insiders bought in the last twelve months.

1.20 0.02 −1.64%
Market cap
$26.4M
P/E
0.0×
Fwd P/E
24.0×
Dividend yield
—
F-score
3/9
Altman Z
0.40
Beneish M
−4.77
Dividend safety
36/100

PetMed Express, Inc. (PETS) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, PetMed Express, Inc. (PETS) trades at a EV/Sales of 0.1×. Over the past ten years it has ranged from 0.0× (December 2025) to 3.7× (July 2017); the current reading is higher than 3% of that period. That is below the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2026 0.1× 5.54%
FY2025 0.1× (5.05%)
FY2024 0.1× (83.89%)
FY2023 0.9× (39.51%)
FY2022 1.5× (22.20%)
FY2021 1.9× 16.10%
FY2020 1.7× 26.66%
FY2019 1.3× (52.69%)
FY2018 2.8× 98.51%
FY2017 1.4× 1.76%

Quarterly newest first

Period EV/Sales Change
Jun 2026 0.2× 15.19%
Mar 2026 0.1× (31.91%)
Dec 2025 0.2× 161.65%
Sep 2025 0.1× (37.15%)
42 more quarters

Against its own ten years

Low 0.0× High 3.7×
Ten-year median 1.3×
Current reading's percentile 2

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on PETS